MEDIA RELEASE
FOR IMMEDIATE RELEASE

12 February 2018

NEW STUDY LINKS GENETIC DIVERSITY OF TUMOURS WITH RESISTANCE TO TREATMENT IN ASIAN LUNG CANCER PATIENTS

*The discovery can potentially lead to more precise treatments for Asian patients.*

**Singapore** – Scientists from A*STAR’s Genome Institute of Singapore (GIS) and medical oncologists from the National Cancer Centre Singapore (NCCS) have discovered that lung cancer tumours in Asian patients contain much higher genetic diversity than previously expected. Hence, this type of tumour tends to develop resistance despite initial tumour shrinkage. With this discovery, scientists and oncologists are better equipped to guide treatments and develop more refined and personalised approaches to common non-small-cell lung carcinoma (NSCLC). The study was published in the international journal *Nature Communications*.

Lung cancer is the most common cause of cancer mortality in the world. It accounts for approximately 19 percent of all cancer-related deaths worldwide and has a mortality rate more than twice that of any other cancer\(^1\). Lung cancer is also the most common type of cancer in Asia\(^2\). The number of incidences and deaths are expected to rise with increased pollution, particularly in large, densely populated Asian cities. Thus, newer and more effective individualised treatment strategies are crucial to tackle the growing threat and improve the quality of patients’ lives.

Lung cancer in Asian patients is characterised by an important mutation in a gatekeeper gene known as the epidermal growth factor receptor, EGFR\(^3\). Gatekeeper genes, also known as the tumour suppressor genes, control and regulate cell cycles. It was discovered that mutations in this gene occur in more than 50 percent of the tumours in Singaporean lung cancer patients. While drugs targeting it are effective in controlling the disease, the response is short-lived. Most patients eventually succumb to cancer relapse in a matter of months or a few years. In some instances, patients do not even respond to these drugs at all. The variability in clinical outcomes, and the tumours’ seemingly inevitable development of resistance to treatment, have intrigued doctors for years, and have remained major stumbling blocks in administering better patient care.

“This joint study is one of the first major efforts to characterise and identify lung tumours in Singaporean patients on a large scale. It has generated a treasure trove of new genetic information and enabled us to perform detailed analyses, leading us to conclude that lung

---

3. The Epidermal Growth Factor Receptor (EGFR) is a gene that can result in cancer if it mutates. In a healthy cell, EGFR allows cells to grow and divide. When mutation occurs, as happens in cancer, the cancer cells continue to grow and divide uncontrollably, forming a mass of cells called a tumour. [https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/epidermal-growth-factor-receptor-egfr-testing-advanced-non-small-cell-lung-cancer](https://www.cancer.net/research-and-advocacy/asco-care-and-treatment-recommendations-patients/epidermal-growth-factor-receptor-egfr-testing-advanced-non-small-cell-lung-cancer)
tumours in Asian patients are surprisingly more complex than previously appreciated,” mentioned Dr Rahul Nahar, the first author of this study and a Research Associate at GIS.

“The study of the genetic complexity of tumours in Asian patients has provided us with new insights as to why they may quickly develop resistance after initial response to anti-EGFR drug inhibitors. We also found that tumours with a high number of drivers, mutations that cause cancer progression, tend to be associated with poor drug response,” explained Dr Axel Hillmer, Principal Investigator at GIS and a co-corresponding author of this study.

“Understanding the comprehensive genetic landscape of these tumours allows us to go beyond single gene mutations (such as EGFR) to better understand the behaviour of individual tumours, and tailor treatments more effectively. Further work needs to be focused on identifying drug combinations or treatment strategies that take into account the tumours’ ability to adapt to different treatments,” said Dr Daniel Tan, Senior Consultant Medical Oncologist at NCCS and the corresponding author of this paper.

Professor Ng Huck Hui, Executive Director of GIS, said, “Timely and comprehensive research on disease states is critical, especially for diseases with a mortality rate as high as lung cancer. The study represents one of the first attempts at such an in-depth analysis of this unique subtype of NSCLC, and has yielded new insights and research directions. Discoveries like this will continue to pave the way for developing increasingly precise treatments.”

This study was funded by the Translational and Clinical Research (TCR) grant from the National Medical Research Council (NMRC), Singapore.
Researchers from Singapore discovered that the EGFR mutant lung cancer in Asians is more varied than its counterpart observed in Caucasians. This suggests that genetic evolution is driving lung cancers into two groups differentiated by patients’ ethnicities.

Notes to Editor:

The research findings described in this media release can be found in the scientific journal *Nature Communications*, under the title, “Elucidating the genomic architecture of Asia EGFR-mutant lung adenocarcinoma through multi-region exome sequencing” by Rahul Nahar¹, Weiwei Zhai², Tong Zhang², Angela Takano³, Alexis J. Khng¹, Yin Yeng Lee¹, Xingliang Liu¹, Chong Hee Lim⁴, Tina P.T. Koh⁴, Zaw Win Aung⁵, Tony Kiat Hon Lim³, Lavanya Veeravalli⁶, Ju Yuan⁹, Audrey S.M. Teo¹, Cheryl X. Chan¹, Huay Mei Poh¹, Ivan M.L. Chua⁷, Audrey Ann Liew⁸, Dawn Ping Xi Lau⁸,¹¹, Xue Lin Kwang⁸,¹¹, Chee Keong Toh⁸, Wan-Teck Lim⁸, Bing Lim⁹, Wai Leong Tam⁹, Eng-Huat Tan⁸, Axel M. Hillmer¹,¹⁰, Daniel S.W. Tan⁸,⁹,¹¹.  

1. Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore 138672.  
2. Human Genetics, Genome Institute of Singapore, Singapore 138672.  
3. Department of Pathology, Singapore General Hospital, Singapore 169608.  
4. Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore 169609.  
5. Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore 169610.
7. Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore 138672.
8. Division of Medical Oncology, National Cancer Centre Singapore, Singapore 169610.
10. Institute of Pathology, University Hospital Cologne, 50937 Cologne, Germany.
11. Cancer Therapeutics Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, Singapore 169610.

#, !, * These authors contributed equally to the study.

Corresponding Authors: Daniel S.W. Tan (daniel.tan.s.w@nccs.com.sg) and Axel M. Hillmer (axel.hillmer@uk-koeln.de).

For media queries and clarifications, please contact:

Lyn Lai
Officer, Office of Corporate Communications
Genome Institute of Singapore, A*STAR
Tel: +65 6808 8258
Email: lai_yilin@gis.a-star.edu.sg

Gillian Tan
Senior Executive, Corporate Communications
National Cancer Centre Singapore (NCCS)
Tel: +65 6236 9529 / 8157 3671
Email: gillian.tan@nccs.com.sg

About A*STAR’s Genome Institute of Singapore (GIS)
The Genome Institute of Singapore (GIS) is an institute of the Agency for Science, Technology and Research (A*STAR). It has a global vision that seeks to use genomic sciences to achieve extraordinary improvements in human health and public prosperity. Established in 2000 as a centre for genomic discovery, the GIS will pursue the integration of technology, genetics and biology towards academic, economic and societal impact.

The key research areas at the GIS include Human Genetics, Infectious Diseases, Cancer Therapeutics and Stratified Oncology, Stem Cell and Regenerative Biology, Cancer Stem Cell Biology, Computational and Systems Biology, and Translational Research.
The genomics infrastructure at the GIS is utilised to train new scientific talent, to function as a bridge for academic and industrial research, and to explore scientific questions of high impact.

For more information about GIS, please visit [www.gis.a-star.edu.sg](http://www.gis.a-star.edu.sg)

**About the Agency for Science, Technology and Research (A*STAR)**

The Agency for Science, Technology and Research (A*STAR) is Singapore’s lead public sector agency that spearheads economic oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.

As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.

We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and Research Institutes, the wider research community and industry. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis.

For more information on A*STAR, please visit [www.a-star.edu.sg](http://www.a-star.edu.sg)

**About National Cancer Centre Singapore (NCCS)**

National Cancer Centre Singapore (NCCS) provides a holistic and multi-disciplinary approach to cancer treatment and patient care. We treat almost 70 per cent of the public sector oncology cases, and they are benefiting from the sub-specialisation of our clinical oncologists. NCCS is also accredited by the US-based Joint Commission International for its quality patient care and safety. To deliver among the best in cancer treatment and care, our clinicians work closely with our scientists who conduct robust cutting-edge clinical and translational research programmes which are internationally recognised. NCCS strives to be a global leading cancer centre, and shares its expertise and knowledge by offering training to local and overseas medical professionals. [www.nccs.com.sg](http://www.nccs.com.sg)